KYSE-30 Orthotopic Mouse Model Service for Esophageal Cancer

By returning human esophageal squamous carcinoma cells to the organ from which they were originally derived, the KYSE-30 orthotopic mouse model offers a far more faithful preclinical setting than conventional flank xenografts for studying tumor growth, local invasion, and therapeutic response in esophageal cancer. Supported by an experienced surgical modeling team and state-of-the-art bioluminescence imaging, Alfa Cytology provides complete assistance with KYSE-30 orthotopic model development, longitudinal monitoring, histopathological characterization, and efficacy evaluation tailored to each research program.

Overview of KYSE-30 Orthotopic Mouse Model for Esophageal Cancer

KYSE-30 belongs to the renowned KYSE series of 21 human esophageal cancer cell lines established at Kyoto University and first described by Shimada and colleagues in 1992. The line was derived from the mucosal surface of a well-differentiated squamous cell carcinoma resected from an untreated 64-year-old Japanese male patient, and was established by first passaging tumor fragments in athymic nude mice before adapting them to in vitro culture — a strategy that helped preserve the biological character of the original tumor. KYSE-30 cells grow as adherent polygonal epithelioid cells with long pseudopods, divide rapidly with a doubling time of approximately 20.8 hours, and carry a densely annotated molecular profile that includes a TP53 splice-acceptor mutation in intron 6, a HRAS p.Gln61Leu mutation, a truncating CDKN2A (p16) alteration, amplification of MYC, CCND1, and c-erbB/HER2, and exceptionally high epidermal growth factor receptor expression (about 1.2 × 10⁷ sites per cell) — features that make the line a staple of receptor tyrosine kinase, cell cycle, and apoptosis research.

Fig 1. Longitudinal bioluminescence imaging of a KYSE30-Luc orthotopic esophageal squamous cell carcinoma model established by implantation of tumor fragments into the abdominal esophagus of nude mice. (Song, Shuai, et al., 2014)

Orthotopic transplantation takes this well-characterized line one step closer to the clinic. Instead of growing as an isolated mass under the skin, KYSE-30 tumors are placed directly on the wall of the abdominal esophagus, where they adhere to and progressively invade the muscularis propria, gradually compromise the esophageal lumen, and drive marked body weight loss — all of which closely parallel the clinical course of esophageal cancer. When luciferase-labeled KYSE-30 cells are used, primary tumor growth at this deep anatomical site can still be followed non-invasively and quantitatively by whole-body imaging in vivo. Published orthotopic studies using this line have reported a 100% tumor take rate, histologically confirmed wall invasion, and no spontaneous distant metastasis, yielding a clean, controlled platform for preclinical drug screening, radiotherapy and combination-therapy evaluation, and mechanistic studies of ESCC progression.

Cell Line Information: KYSE-30

The KYSE-30 cell line is one of the most thoroughly documented ESCC models available, with authenticated deposits in multiple international repositories and a molecular profile defined by large-scale sequencing projects. Its key characteristics are summarized below.

Our Services

Focusing exclusively on preclinical oncology services, Alfa Cytology unites authenticated KYSE-30 cell resources, refined microsurgical implantation techniques, and luciferase-based imaging to produce dependable orthotopic esophageal cancer models, complete with downstream histopathology and molecular analysis.

Workflow of KYSE-30 Orthotopic Mouse Model Construction

The KYSE-30 orthotopic model is commonly built through a two-stage strategy: a luciferase-labeled tumor is first expanded subcutaneously as a donor, and small fragments of that tumor are then surgically grafted onto the esophageal wall of recipient mice. The typical workflow is as follows.

1. Reporter labeling and quality control: KYSE-30 cells are stably transduced with a luciferase reporter (e.g., pLVX-Luciferase), antibiotic-selected to obtain uniformly expressing clones, and verified for luciferase activity, STR identity, and mycoplasma negativity before use.
2. Subcutaneous expansion of donor tumors: KYSE-30-Luc cells (typically 1 × 10⁶ cells in 100 μL PBS) are injected into the flank of immunodeficient nude mice and grown until the tumor reaches approximately 0.5–0.8 cm in diameter.
3. Tumor fragment preparation: The donor tumor is aseptically resected and sectioned into uniform fragments of about 1 mm³, which are kept chilled on ice until implantation.
4. Surgical exposure of the abdominal esophagus: Recipient mice are anesthetized, a small transverse incision is made in the left upper abdomen, the liver is gently raised with a sterile cotton ball, and traction on the stomach exposes the abdominal esophagus.
5. Orthotopic implantation: The esophageal serosa is lightly abraded with toothed forceps to provoke a mild inflammatory reaction that promotes fragment adhesion, and the tumor fragments are then sutured onto the esophageal wall with fine 8-0 absorbable sutures.
6. Closure and perioperative care: The abdominal wall and skin are closed with 6-0 absorbable sutures, followed by supportive care and close monitoring of body weight, hydration, and overall condition during recovery.
7. Longitudinal monitoring and endpoint analysis: Tumor growth is tracked by serial whole-body bioluminescence imaging together with body weight records in vivo; at study end, primary tumors are weighed, and esophageal tissue is examined by H&E staining for muscularis propria invasion, with major organs screened for metastasis.

Fig 2. KYSE-30 orthotopic mouse model construction workflow.

Case Study-KYSE-30 Orthotopic Mouse Model Development

Alfa Cytology has utilized the KYSE-30 orthotopic platform in a range of preclinical research projects, from model establishment and imaging-based monitoring to candidate drug efficacy testing and radiotherapy response studies. Across these programs, luciferase-labeled KYSE-30 tumors consistently engrafted at the esophageal site and provided stable, quantifiable imaging signals and clear histopathological readouts of local invasion. Detailed project information and customized study designs can be shared upon request.

Why Choose Alfa Cytology?

A technically demanding orthotopic model deserves a partner with the right combination of surgical skill, imaging infrastructure, and quality discipline — and that is exactly what Alfa Cytology brings to every KYSE-30 study.

• Mastery of fragment-based orthotopic surgery, a method with a documented 100% engraftment rate for this cell line in published studies.
• Every batch of KYSE-30 cells is STR-verified and mycoplasma-tested, safeguarding the identity of your model.
• Non-invasive luciferase imaging allows quantitative tracking of deep-seated esophageal tumors in vivo without serial sacrifice.
• Study designs can be adapted for single agents, combination regimens, radiotherapy schedules, and mechanistic endpoints.
• Terminal readouts go beyond tumor size to include H&E-confirmed wall invasion and metastasis screening.
• Direct scientific communication and dependable timelines keep your program moving from design to data delivery.

Contact Us

Looking for a reliable KYSE-30 orthotopic model to power your esophageal cancer research? Contact us today, and our team will work with you to define a study plan that fits your objectives and timeline. Reach out to Alfa Cytology now and move your preclinical program forward with confidence.

For research use only. Not intended for any clinical use.